1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
TAKE Solutions Limited

TAKE Solutions Limited

TAKE.NS
TAKE Solutions LimitedIN flagNational Stock Exchange of India
30.02
INR
-0.60
- -
4.39BMarket Cap
TAKE Solutions Limited
TAKE.NS
(National Stock Exchange of India)

Recent

price

30.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
41.69
58.64
69.33
67.96
60.87
85.81
105.46
120.62
139.53
151.34
52.93
44.63
12.93
0.25
- -
3.7
- -
Revenue per Share
6.13
7.13
6.62
4.83
5.82
9.97
11.22
12.19
12.13
-0.85
-30.91
-53.5
-6.86
-8.18
2.53
0.74
2.73
Basic EPS, GAAP
-12.25
6.12
3.63
2.18
3.81
-0.26
-7.2
-1.91
2.71
1.96
9.03
6.09
-0.85
0.1
-1.11
-0.28
- -
Free Cash Flow per Basic Share
0.21
1.13
1.86
1
1
1.23
1.03
1
1.94
0.49
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.58
10.22
15.32
16.98
20.62
28.44
36.85
47.04
52.88
51.57
20.33
-33.07
-38.68
-46.87
-44.08
1.01
- -
Book Value per Share
2.68
6.55
14.09
17.69
24.38
21.14
42.89
69.84
45.16
47.19
28.57
8.5
3.71
-0.73
1.39
2.11
- -
Tangible Book Value per Share
120
120
120
120
120
120
127
132
146
146
146
146
146
146
148
147
147
Basic Weighted Avg Shares
5,003
7,037
8,320
8,155
7,304
10,301
13,446
15,872
20,390
22,129
7,740
6,526
1,891
36
- -
542
- -
Sales/Revenue/Turnover
16.92
16.83
13.83
8.63
12.35
13.54
13.17
12.81
11.35
0.8
-19.37
-9.21
3.08
-181.04
- -
-3.55
- -
Operating Margin (%)
48
79
223
373
203
248
874
1,041
1,535
1,669
1,154
959
168
79
- -
- -
- -
Depreciation Expense
736
856
795
580
699
1,197
1,431
1,605
1,773
-124
-4,520
-7,823
-1,003
-1,196
375
108
403
Net Income, GAAP
8.12
18.33
16.95
1.59
6.37
13.86
11.44
14.96
17.29
- -
- -
- -
- -
- -
- -
3.62
- -
Effective Tax Rate (%)
14.7
12.16
9.55
7.11
9.57
11.62
10.64
10.11
8.7
-0.56
-58.4
-119.86
-53.03
-3,320.93
- -
20.02
- -
Profit Margin (%)
1,478
1,766
2,023
1,993
2,091
1,895
4,435
7,630
4,482
5,391
3,366
796
-107
-539
76
185
- -
Working Capital
1,313
1,235
830
576
8
676
488
545
389
2,127
1,613
278
139
66
- -
- -
- -
LT Debt
2,818
3,796
4,661
5,183
5,805
6,792
9,532
13,367
15,274
15,854
11,243
1,806
1,086
-89
205
310
- -
Total Equity
17.79
19.4
15.86
10.25
11.82
13.73
14.24
12.06
10.32
- -
- -
- -
- -
- -
-31.04
-7.19
- -
Return on Invested Capital (%)
34.81
31.82
21.85
14.55
14.88
20.25
20.59
20.24
17.28
- -
- -
- -
- -
- -
-6.06
-3.51
-5.87
Return on Capital (%)
64.02
96.34
51.85
29.93
30.98
40.64
35.27
29.47
25.48
-1.62
-85.98
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
146
- -
Market Capitalization
2,329
974
1,322

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
236
- -
Cash, Cash Equivalents & STI
- -
34
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
160
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-44.27%
-102.46%
51.03%
Free Cash Flow
121.77%
-320.31%
-74.79%
Net Income, GAAP
329.52%
-39.44%
-71.04%
Sales/Revenue/Turnover
- -
- -
1,404.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36
1
- -
132
36
2025
- -
- -
- -
- -
- -
2026
- -
- -
542
- -
542

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
-0.11
-0.15
- -
-8.18
2025
-0.26
-0.11
3.26
-0.33
2.53
2026
-0.06
0.07
0.29
- -
0.74

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
Neurogene Inc. (NGNE)
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
Theravance Biopharma, Inc. (TBPH)
Lumosa Therapeutics Co., Ltd. (6535.TWO)
Cybin Inc. (CYBN.NE)
Business
TAKE Solutions Limited, operating alongside its various divisions, delivers specialized services and technology-driven platforms for the life sciences and supply chain management sectors across North America, the Asia Pacific, and European markets. The company concentrates on providing comprehensive clinical development services, encompassing full-spectrum clinical research, data management, and generics support, including advanced bioavailability and bioequivalence studies. Under its Navitas Life Sciences brand, it offers expertise in navigating regulatory pathways, ensuring compliance, and managing pharmacovigilance and safety protocols. Furthermore, TAKE Solutions extends its capabilities into digital healthcare through artificial intelligence and machine learning for medical decision-making, along with cloud adoption and mobile solutions aimed at patient-centricity, payer insights, and sophisticated medical device technologies. Within supply chain management, the firm provides niche engineering, collaboration tools, and product re-engineering services, utilizing proprietary technology to streamline logistics and enhance compliance. The clientele comprises a diverse range of innovator biopharmaceutical and medical device enterprises, alongside generics producers, and governmental health organizations. Established in 2000, TAKE Solutions Limited maintains its principal offices in Chennai, India, and functions as a publicly traded entity with significant oversight from TAKE Solutions Pte. Limited.